Herbert I Hurwitz

Herbert I Hurwitz

UNVERIFIED PROFILE

Are you Herbert I Hurwitz?   Register this Author

Register author
Herbert I Hurwitz

Herbert I Hurwitz

Publications by authors named "Herbert I Hurwitz"

Are you Herbert I Hurwitz?   Register this Author

100Publications

1831Reads

25Profile Views

The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2019 Aug 11;84(2):383-392. Epub 2019 Jun 11.

Section of Clinical Pharmacology, Department of Medicine, The Geisel School of Medicine at Dartmouth and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03880-9DOI Listing
August 2019

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.

Br J Cancer 2018 12 29;119(12):1451-1455. Epub 2018 Nov 29.

University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0304-6
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0304-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288128PMC
December 2018

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.

Mol Cancer Ther 2018 10 11;17(10):2248-2256. Epub 2018 Jul 11.

Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0916DOI Listing
October 2018

Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.

Radiology 2017 10 8;285(1):311-318. Epub 2017 Aug 8.

From the Department of Radiology, Division of Vascular & Interventional Radiology (J.R., D.M., R.T.G., G.J., W.C., P.V.S., W.P.R., D.R.S., C.Y.K.), and Department of Medicine (A.B.N., M.D.S., J.C.B., H.I.H.), Duke University Medical Center, Box 3808 Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017162555DOI Listing
October 2017

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Cancer Chemother Pharmacol 2017 03 25;79(3):611-619. Epub 2017 Feb 25.

Duke Cancer Institute, Duke University Medical Center, Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3256-2DOI Listing
March 2017

Development of a Novel c-MET-Based CTC Detection Platform.

Mol Cancer Res 2016 06 7;14(6):539-47. Epub 2016 Mar 7.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina. Department of Pharmacology and Cancer Biology, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-16-0011DOI Listing
June 2016

HER2 testing in metastatic colorectal cancer: ready for prime time?

Clin Adv Hematol Oncol 2016 Apr;14(4):235-7

Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
April 2016

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J Clin Oncol 2015 Dec 8;33(34):4039-47. Epub 2015 Sep 8.

Herbert I. Hurwitz, Duke University Medical Center, Durham, NC; Nikhil Uppal, New York University Langone Arena Oncology, Lake Success, NY; Stephanie A. Wagner, Indiana University Melvin and Bren Simon Cancer Center; Robert Manges, Investigative Clinical Research of Indiana, Indianapolis, IN; Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, TN; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Seaborn M. Wade III, Virginia Cancer Institute, Richmond, VA; John J. Nemunaitis, Mary Crowley Medical Research Center, Dallas, TX; Philip J. Stella, St Joseph Mercy Health System, Alexander Cancer Care Center, Ann Arbor, MI; J. Marc Pipas, Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, NH; Zev A. Wainberg, University of California, Los Angeles, Los Angeles, CA; and William M. Garrett, Deborah S. Hunter, Jason Clark, Lance Leopold, Victor Sandor, and Richard S. Levy, Incyte Corporation, Wilmington, DE.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/09/03/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.4578
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.4578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089161PMC
December 2015

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.

Support Care Cancer 2015 May 24;23(5):1311-9. Epub 2014 Oct 24.

Duke Cancer Institute, Seeley G. Mudd Bldg., 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-014-2465-z
Publisher Site
http://dx.doi.org/10.1007/s00520-014-2465-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973630PMC
May 2015

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

J Natl Cancer Inst 2015 Mar 24;107(3). Epub 2015 Feb 24.

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA (FL, DY, WZ, HJL); U.O. Oncologia Medica, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy (FL, CC, CA, AF); Genentech, Inc., South San Francisco, CA (LY, SF, CL, SJS, TM); Department of General, Visceral, and Tumor Surgery, University of Cologne, Cologne, Germany (MKHM); Response Genetics, Inc., Los Angeles, CA (MKHM); Department of Medical Oncology and Transplantation, Duke University, Durham, NC (HIH); Memorial Sloan-Kettering Cancer Center, New York, NY (LS) Current Affiliations: Onyx Pharmaceuticals, Inc. South San Francisco, CA (SF); Biocenter, Physiological Chemistry 1, University of Wuerzburg, Wuerzburg, Germany (SJS); Biomarker, Translational and Predictive Medicine Consulting, San Francisco, CA (TM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565528PMC
March 2015

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Feb 20;75(2):343-52. Epub 2014 Dec 20.

Duke Cancer Institute, Duke University Medical Center, Box 3052, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2647-xDOI Listing
February 2015

A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.

Comput Biol Med 2015 Feb 9;57:123-9. Epub 2014 Dec 9.

Department of Biostatistics and Bioinformatics & Duke Cancer Biostatistics, Duke University School of Medicine, Durham, NC, United States; School of Public Health, Li Ka Shing Faculty of Medicine, Pok Fu Lam, Hong Kong SAR, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2014.11.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306627PMC
February 2015

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.

Gynecol Oncol 2014 Nov 30;135(2):349-58. Epub 2014 Aug 30.

Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.08.033DOI Listing
November 2014

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Invest New Drugs 2014 Oct 5;32(5):851-9. Epub 2014 Jul 5.

Department of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0129-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169868PMC
October 2014

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Clin Genitourin Cancer 2014 Aug 14;12(4):241-50. Epub 2013 Nov 14.

Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.11.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623321PMC
August 2014

Palliative treatment of metastatic colorectal cancer: what is the optimal approach?

Curr Oncol Rep 2014 ;16(1):363

Department of Medicine, Division of Medical Oncology, Duke University Medical Center, DUMC 2823, Durham, NC, 27710, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-013-0363-z
Publisher Site
http://dx.doi.org/10.1007/s11912-013-0363-zDOI Listing
June 2014

Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report.

JOP 2014 May 27;15(3):266-8. Epub 2014 May 27.

Duke University School of Medicine, Duke University Medical Center, Durham, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6092/1590-8577/2407DOI Listing
May 2014

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Clin Cancer Res 2014 Jan 30;20(2):480-9. Epub 2013 Oct 30.

Authors' Affiliations: Sarah Cannon Research Institute, Nashville, Tennessee; Pinnacle Oncology Hematology, Scottsdale, Arizona; Duke University Medical Center, Durham, North Carolina; Huntsman Cancer Institute, Salt Lake City, Utah; and Acceleron Pharma, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1840DOI Listing
January 2014

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Clin Cancer Res 2013 Dec 4;19(24):6957-66. Epub 2013 Oct 4.

Authors' Affiliations: Division of Medical Oncology; Alliance Statistics and Data Center, Duke University Medical Center; Durham, North Carolina; Section of Hematology/Oncology, University of Chicago Cancer Research Center; Chicago, Illinois; Department of Surgery, Brigham and Women's Hospital & Harvard Medical School; Boston, Massachusetts; Department of Internal Medicine, Ohio State University; Columbus, Ohio; and Division of Medical Oncology, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-0926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219241PMC
December 2013

Understanding and targeting resistance to anti-angiogenic therapies.

J Gastrointest Oncol 2013 Sep;4(3):253-63

Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2078-6891.2013.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712298PMC
September 2013

Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Expert Opin Biol Ther 2013 Aug 26;13(8):1187-96. Epub 2013 Jun 26.

Duke University Medical Center, Duke Cancer Institute, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.810717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131847PMC
August 2013

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

Invest New Drugs 2013 Jun 6;31(3):751-9. Epub 2012 Oct 6.

Department of Medical Oncology, Erasmus University Medical Center/Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-012-9885-8
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9885-8DOI Listing
June 2013

Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.

Anticancer Drugs 2013 Mar;24(3):237-50

Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e32835d29fdDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828660PMC
March 2013

Ziv-aflibercept: binding to more than VEGF-A--does more matter?

Nat Rev Clin Oncol 2013 Jan 13;10(1):10-1. Epub 2012 Nov 13.

Duke University Medical Center, Box 3182, 2301 Erwin Road, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.197DOI Listing
January 2013

Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.

Oncologist 2012 3;17(4):513-24. Epub 2012 Apr 3.

Duke University Medical Center, DUMC 2823, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2012-0003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336830PMC
October 2012

Anti-VEGF therapies in the clinic.

Cold Spring Harb Perspect Med 2012 Oct 1;2(10). Epub 2012 Oct 1.

Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/c
Publisher Site
http://dx.doi.org/10.1101/cshperspect.a006577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475399PMC
October 2012

Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.

Oncologist 2012 10;17(1):9-10. Epub 2012 Jan 10.

Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2011-0358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267828PMC
June 2012

Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.

J Chromatogr B Analyt Technol Biomed Life Sci 2012 Jun 20;898:32-7. Epub 2012 Apr 20.

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S157002321200224
Publisher Site
http://dx.doi.org/10.1016/j.jchromb.2012.04.010DOI Listing
June 2012

Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.

Int J Radiat Oncol Biol Phys 2011 Nov 23;81(3):654-9. Epub 2010 Sep 23.

Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016100086
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2010.06.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121739PMC
November 2011

Highlights in metastatic colorectal cancer from the American Society of Clinical Oncology Annual Meeting, June 3-7, 2011, Chicago, Illinois.

Clin Adv Hematol Oncol 2011 Jul;9(7 Suppl 14):1-24

Duke Cancer Institute, Duke Comprehensive Cancer Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
July 2011

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

J Clin Oncol 2011 May 21;29(13):1757-64. Epub 2011 Mar 21.

Duke University Medical Center, Division of Hematology and Oncology, PO Box 3052, Durham, NC 27710-0001, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.32.3220
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.32.3220DOI Listing
May 2011

Phase I trial of pazopanib in patients with advanced cancer.

Clin Cancer Res 2009 Jun 9;15(12):4220-7. Epub 2009 Jun 9.

Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2740DOI Listing
June 2009

Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.

J Gastrointest Surg 2009 Jan 7;13(1):74-84. Epub 2008 Aug 7.

Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-008-0617-5DOI Listing
January 2009

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

Int J Radiat Oncol Biol Phys 2009 Jan 19;73(1):148-53. Epub 2008 Sep 19.

Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.07.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142576PMC
January 2009

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

J Clin Oncol 2009 Jan 8;27(2):199-205. Epub 2008 Dec 8.

Department of Medicine, Division of Hematology & Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095-7059, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2008.17.7931
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.17.7931DOI Listing
January 2009

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.

Oncologist 2008 Sep 5;13(9):1021-9. Epub 2008 Sep 5.

Division of Hematology/Oncology, University of California at Los Angeles , California 90095-7059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0003DOI Listing
September 2008

Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.

Int J Radiat Oncol Biol Phys 2007 Dec 6;69(5):1436-41. Epub 2007 Aug 6.

Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.05.006DOI Listing
December 2007

Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.

Int J Radiat Oncol Biol Phys 2007 Nov;69(3):770-6

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.03.035DOI Listing
November 2007

Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?

Nat Clin Pract Oncol 2007 Apr 13;4(4):214-5. Epub 2007 Feb 13.

Duke South Clinics, Duke University Medical Center, Box 3052, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncponc0748
Publisher Site
http://dx.doi.org/10.1038/ncponc0748DOI Listing
April 2007

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2007 Jan 4;59(1):139-47. Epub 2006 Jul 4.

Division of Hematology and Oncology, Duke University Medical Center, P.O. Box 3052, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0267-9DOI Listing
January 2007

The role of targeted therapy in the treatment of colorectal cancer.

Clin Adv Hematol Oncol 2006 Aug;4(8 Suppl 17):1-10; quiz 11-2

University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
August 2006

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Clin Colorectal Cancer 2006 May;6(1):66-9

Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2006.n.023DOI Listing
May 2006

Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.

Clin Adv Hematol Oncol 2005 Dec;3(12):1-10; quiz 11

University of North Carolina, Chapel Hill, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
December 2005